Hutchison China MediTech Limited (LON:HCM)‘s stock had its “buy” rating reiterated by analysts at Beaufort Securities in a report issued on Wednesday.

Separately, Panmure Gordon reiterated a “buy” rating and issued a GBX 2,630 ($32.87) target price on shares of Hutchison China MediTech Limited in a report on Wednesday, February 1st.

Hutchison China MediTech Limited (LON:HCM) opened at 2165.00 on Wednesday. The company’s 50-day moving average is GBX 2,212.77 and its 200-day moving average is GBX 2,001.12. The firm’s market capitalization is GBX 1.31 billion. Hutchison China MediTech Limited has a one year low of GBX 1,612.50 and a one year high of GBX 2,470.00.

This report was published by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international copyright law. The correct version of this report can be accessed at http://www.watchlistnews.com/hutchison-china-meditech-limited-hcm-stock-rating-reaffirmed-by-beaufort-securities/1121508.html.

In related news, insider Michael Howell sold 3,000 shares of the stock in a transaction on Monday, November 21st. The stock was sold at an average price of GBX 1,890 ($23.62), for a total value of £56,700 ($70,857.29).

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.